Why Is QUEST DIAGNOSTICS IN (DGX) Stock Moving Today?

DGX stock rose 8.61% to $227.90 on Wednesday, driven by Quest Diagnostics' second-quarter earnings beat and upward revision of full-year guidance. The company reported stronger-than-expected revenue and earnings per share, while also raising its 2026 revenue and EPS forecasts. The move reflects improved operational performance and growing demand for diagnostic services.

What Happened

Quest Diagnostics reported Q2 2026 results that exceeded expectations, with revenue growth of 10% and volume growth of 13%. The company attributed the strong performance to organic growth, operational efficiencies, and the expansion of its Haystack MRD testing. As a result, Quest raised its 2026 revenue guidance to $11.95 billion to $12.05 billion, up from a previous range of $11.78 billion to $11.9 billion. The EPS guidance was also increased to $11.05 to $11.25, above the $10.76 consensus estimate. These updates signaled confidence in the company's ability to capitalize on rising demand for diagnostic services and new product innovations.

What The Data Shows

The stock's 8.61% gain on Wednesday marked a significant intraday move, outpacing its 52-week range of $165.78 to $219.20. With a market cap of $22.9 billion, Quest Diagnostics trades at a P/E of 23.2 and has delivered 11% revenue growth in the trailing twelve months. The stock's beta of 0.57 suggests it is less volatile than the broader market. Recent insider transactions included two sales totaling $3.6 million over the past 90 days, while congressional trades showed five purchases in the same period. Social chatter on X was minimal, with only one post in the last 24 hours.

What To Watch

The company has already reported its Q2 2026 earnings and guidance. Investors should monitor the breadth of analyst coverage and any follow-up commentary from industry experts.